Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

Background The inhaled lung-selective pan-Janus kinase inhibitor nezulcitinib had favourable safety and potential efficacy signals in part 1 of a phase 2 trial in patients with severe COVID-19, supporting progression to part 2.Methods Part 2 was a randomised, double-blind phase 2 study (NCT04402866)...

Full description

Bibliographic Details
Main Authors: Dave Singh, Tuan Nguyen, Jacky Woo, Rajeev Saggar, Nathan D Pfeifer, David A Lombardi, Brett Haumann, John Belperio, Maxim Bogus, Valentyn Moskalenko, David L Bourdet, Elad Kaufman, Corbin G Thompson, Edmund J Moran
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/10/1/e001627.full

Internet

https://bmjopenrespres.bmj.com/content/10/1/e001627.full

Similar Items